Engineered FGF19(ΔKLB) protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model

BACKGROUND: The major safety concern of the clinical application of wild type FGF19 (FGF19(WT)) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant - FGF19(ΔKLB), which have same effects on glycemic control and bile acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Lu, Zhao, Tiantian, Huang, Lei, Pan, Xiaomin, Wu, Tianzhen, Feng, Xin, Chen, Taoli, Wu, Jiamin, Niu, Jianlou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548598/
https://www.ncbi.nlm.nih.gov/pubmed/37789318
http://dx.doi.org/10.1186/s12896-023-00810-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548598/
https://www.ncbi.nlm.nih.gov/pubmed/37789318
http://dx.doi.org/10.1186/s12896-023-00810-9

Ejemplares similares